{"id":3145,"date":"2023-10-01T18:46:21","date_gmt":"2023-10-01T18:46:21","guid":{"rendered":"https:\/\/www.laboratoriosrubio.com\/?p=3145"},"modified":"2026-01-13T15:47:47","modified_gmt":"2026-01-13T15:47:47","slug":"pharmaceutical-industry-in-spain","status":"publish","type":"post","link":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/","title":{"rendered":"The Spanish Pharmaceutical Industry"},"content":{"rendered":"<p>The\u00a0pharmaceutical industry in Spain\u00a0is one of the most dynamic, strategic, and innovation-driven sectors of the nation\u2019s economy. Accordint to <a href=\"https:\/\/www.farmaindustria.es\/web\/prensa\/notas-de-prensa\/2025\/05\/20\/la-inversion-en-id-de-las-companias-farmaceuticas-innovadoras-supera-los-1-500-millones-de-euros-en-2024\/\">Farmaindustria,<\/a> Investment in R&amp;D by innovative pharmaceutical companies exceeds \u20ac1.5 billion in 2024. Beyond supplying safe and effective medicines to Spanish patients, the sector plays a pivotal role in Europe\u2019s pharmaceutical ecosystem, offering cutting-edge research, production capabilities, and international exports.<\/p>\n<p>According to data from\u00a0<a href=\"https:\/\/www.semrush.com\/swa\/checker\/www.farmaindustria.com\">Farmaindustria<\/a>\u00a0(2024), Spain is home to more than\u00a0134 innovative pharmaceutical companies, which together represent\u00a070.8% of prescription medicine sales\u00a0in the national market. The sector generates\u00a0over 47,000 direct jobs\u00a0(most of them highly skilled scientists and technicians) and around\u00a0200,000 indirect jobs\u00a0across its supply chain.<\/p>\n<p>This makes the industry not only a\u00a0cornerstone of Spain\u2019s healthcare system, but also a key contributor to the\u00a0European Union\u2019s pharmaceutical resilience strategy, especially after lessons learned during COVID-19.<\/p>\n<p>In this article, we will explore:<\/p>\n<ul>\n<li>The size and growth of the Spanish pharmaceutical market<\/li>\n<li>Its strategic role in the national and EU economy<\/li>\n<li>Advances in\u00a0innovation, R&amp;D, and clinical trials<\/li>\n<li>The\u00a0regulatory framework and institutions\u00a0ensuring safety and ethics<\/li>\n<li>Spain\u2019s role in\u00a0pharmaceutical manufacturing and exports<\/li>\n<li>Contributions to\u00a0sustainability and corporate responsibility<\/li>\n<li>A\u00a0Spain pharmacy market outlook\u00a0highlighting future opportunities and challenges<\/li>\n<\/ul>\n<div class=\"flex-1 overflow-hidden\">\n<div class=\"react-scroll-to-bottom--css-owelb-79elbk h-full dark:bg-gray-800\">\n<div class=\"react-scroll-to-bottom--css-owelb-1n7m0yu\">\n<div class=\"flex flex-col text-sm dark:bg-gray-800\">\n<div class=\"group w-full text-token-text-primary border-b border-black\/10 gizmo:border-0 dark:border-gray-900\/50 gizmo:dark:border-0 bg-gray-50 gizmo:bg-transparent dark:bg-[#444654] gizmo:dark:bg-transparent\" data-testid=\"conversation-turn-71\">\n<div class=\"p-4 justify-center text-base md:gap-6 md:py-6 m-auto\">\n<div class=\"flex flex-1 gap-4 text-base mx-auto md:gap-6 gizmo:gap-3 gizmo:md:px-5 gizmo:lg:px-1 gizmo:xl:px-5 md:max-w-2xl lg:max-w-[38rem] gizmo:md:max-w-3xl gizmo:lg:max-w-[40rem] gizmo:xl:max-w-[48rem] xl:max-w-3xl }\">\n<div class=\"relative flex w-[calc(100%-50px)] flex-col gap-1 gizmo:w-full md:gap-3 lg:w-[calc(100%-115px)] agent-turn\">\n<div class=\"flex flex-grow flex-col gap-3 max-w-full\">\n<div class=\"min-h-[20px] flex flex-col items-start gap-3 overflow-x-auto whitespace-pre-wrap break-words\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<h2><strong>Spain\u2019s Pharmaceutical Market at a Glance<\/strong><\/h2>\n<p>The\u00a0pharmaceutical industry in Spain\u00a0is among the top five in Europe, alongside Germany, France, Italy, and the UK. The most current official statistics and analysis from <a href=\"https:\/\/www.semrush.com\/swa\/checker\/www.farmaindustria.com\">Farmaindustria<\/a> (2024) confirm Spain&#8217;s pharmaceutical industry as a strategic pillar with record figures in production, employment, innovation, and exports, providing a detailed snapshot for 2024.<\/p>\n<p>The\u00a0pharmaceutical industry in Spain\u00a0is among the top five in Europe, alongside Germany, France, Italy, and the UK. The most current official statistics and analysis from<\/p>\n<h2><strong>Spain\u2019s Pharmaceutical Market at a Glance<\/strong><\/h2>\n<p>The\u00a0pharmaceutical industry in Spain\u00a0is among the top five in Europe, alongside Germany, France, Italy, and the UK. The most current official statistics and analysis from <a href=\"https:\/\/www.semrush.com\/swa\/checker\/www.farmaindustria.com\">Farmaindustria<\/a> (2024) confirm Spain&#8217;s pharmaceutical industry as a strategic pillar with record figures in production, employment, innovation, and exports, providing a detailed snapshot for 2024.<\/p>\n<h3><strong>Sector Overview 2024<\/strong><\/h3>\n<ul>\n<li>Spain\u2019s pharmaceutical manufacturing reached\u00a0\u20ac23 billion, a 40% increase over three years, representing nearly 30% of all high-tech manufacturing output.<\/li>\n<li>The country is home to\u00a0174 production plants\u00a0(106 for human medicines), reaffirming its strength in manufacturing and industrial flexibility.<\/li>\n<li>The sector remains the\u00a0fifth-largest exporter\u00a0in Spain, with foreign sales of over\u00a0\u20ac20 billion\u00a0in 2024.<\/li>\n<\/ul>\n<h3><strong>Employment and Quality<\/strong><\/h3>\n<ul>\n<li>56,000 direct jobs\u00a0(up from 47,000 previously reported), 96% of which are permanent contracts.<\/li>\n<li>The total employment impact reaches\u00a0270,000\u00a0when indirect and induced jobs are included.<\/li>\n<li>70% of employees are university graduates, and the industry is a leader in productivity, nearly double the Spanish average.<\/li>\n<\/ul>\n<h3><strong>Research and Innovation<\/strong><\/h3>\n<ul>\n<li>R&amp;D investment\u00a0exceeded \u20ac1.5 billion\u00a0in 2024, representing 20% of all industrial R&amp;D nationally.<\/li>\n<li>Spain is now the\u00a0leading European country in clinical trial participation, consolidating its reputation as a biomedical innovation hub.<\/li>\n<li>60% of pharmaceutical R&amp;D investment goes to clinical trials, and 1 in 4 trials targets rare diseases.<\/li>\n<\/ul>\n<h3><strong>Regulatory and Strategic Developments<\/strong><\/h3>\n<ul>\n<li>The Spanish government launched the &#8220;Strategia de la Industria Farmac\u00e9utica 2024-2028,&#8221; designating pharma as a pillar for future industrial growth and international competitiveness.<\/li>\n<li>Ongoing regulatory reforms touch drug pricing, financing, public procurement, patent legislation, and environmental compliance\u2014positioning Spain for global competitiveness.<\/li>\n<\/ul>\n<h3><strong>Access to Innovation<\/strong><\/h3>\n<ul>\n<li>In 2024, Spain incorporated 62% of the innovative medicines authorized by the EU between 2019\u20132022 into national funding\u2014showing improvement but still trailing Germany, France, and Italy.<\/li>\n<li>Time from European approval to Spanish patient access averages 22 months, reflecting significant administrative and pricing hurdles.<\/li>\n<\/ul>\n<h3><strong>Diversity, ESG, and Sustainability<\/strong><\/h3>\n<ul>\n<li>56% of employees are women, with 45% female representation in management.<\/li>\n<li>The ESG commitments include 80% of leading companies targeting net-zero emissions by 2040, use of renewable energy, and advanced recycling programs.<\/li>\n<\/ul>\n<p>These metrics, directly sourced from the latest official report, demonstrate Spain\u2019s climb toward innovation and global leadership, with clear progress in most key areas during 2024.<\/p>\n<h3><strong>Spain pharmacy market outlook<\/strong><\/h3>\n<p>The Spain pharmacy market will grow through rising demand for personalized medicine, expanded biosimilar production, and adoption of digital health tools like AI diagnostics and telepharmacy.<\/p>\n<ul>\n<li>Increased demand for\u00a0personalized medicine\u00a0and\u00a0biologics.<\/li>\n<li>Greater production of\u00a0biosimilars, reducing costs for the healthcare system.<\/li>\n<li>Growth in\u00a0digital health technologies\u00a0(AI diagnostics, telepharmacy).<\/li>\n<li>Expansion of\u00a0manufacturing for global markets, with Spain positioned as a key EU production and distribution hub.<\/li>\n<\/ul>\n<p>By 2030, revenues are projected to exceed \u20ac25 billion, with exports contributing more than half of industry value (<a href=\"https:\/\/www.statista.com\/topics\/4426\/charlotte-hornets\/#topicOverview\">Statista<\/a>, Farmaindustria).<\/p>\n<h2><strong>Strategic Role in the National and EU Economy<\/strong><\/h2>\n<p>Spain\u2019s pharmaceutical sector is formally classified as a\u00a0strategic industry\u00a0by the national government and integrated into the EU\u2019s industrial policy, highlighted by the Pharmaceutical Industry <a href=\"https:\/\/www.dlapiper.com\/en\/insights\/blogs\/cortex-life-sciences-insights\/2024\/spanish-pharmaceutical-industry-strategy-2024-2028\">Strategy 2024\u20132028<\/a>, which designates it as a pillar for Spain\u2019s economic and technological sovereignty. This policy prioritizes the sector\u2019s development, resilience, and autonomy, positioning <a href=\"https:\/\/practiceguides.chambers.com\/practice-guides\/life-sciences-2025\/spain\/trends-and-developments\">Spain<\/a> as a reference point for biomedical research and pharmaceutical production in Europe.<\/p>\n<h3><strong>Pharma\u2019s contribution to GDP and employment<\/strong><\/h3>\n<p>The pharmaceutical industry generates\u00a0more than \u20ac27 billion in value added, representing nearly\u00a02% of Spain\u2019s GDP, and is supported by strategic public\u2013private initiatives like <a href=\"https:\/\/www.mintur.gob.es\/portalayudas\/profarma\/Paginas\/index.aspx\">.<\/a> The industry directly employs\u00a0over 56,000 professionals, with total sectoral employment exceeding\u00a0270,000 jobs\u00a0when accounting for indirect and induced impacts\u2014most in high-value R&amp;D, manufacturing, and distribution roles. These figures underscore the sector\u2019s multiplier effects and high productivity, making pharma one of the top contributors to economic growth and quality employment in Spain.<\/p>\n<h3><strong>Importance to healthcare and EU supply chain<\/strong><\/h3>\n<p>Pharmaceuticals are vital for\u00a0public health, ensuring rapid access to innovative medicines and safeguarding the sustainability of the National Health System. The government\u2019s strategic classification emphasizes pharma\u2019s role in\u00a0national security\u00a0and supply-chain resilience\u2014minimizing risks caused by external dependencies and disruptions. Spain&#8217;s capacity for localized production secures essential supplies, supporting the EU-wide push for strategic autonomy in health technologies and medicines.<\/p>\n<h3><strong>Leading hubs: Barcelona, Madrid, and Catalonia BioRegion<\/strong><\/h3>\n<p>Barcelona and Madrid\u00a0are recognized as major pharma hubs, hosting leading multinational firms, advanced research centers, and specialized hospitals. Both cities offer infrastructure, talent, and connectivity that attract domestic and global investment, and drive collaborative projects across manufacturing, R&amp;D, and clinical innovation. This cluster effect amplifies the geographic and sectoral competitiveness of Spain\u2019s pharmaceutical landscape.<\/p>\n<h3><strong>Role of Catalonia BioRegion in Biotech Innovation<\/strong><\/h3>\n<p>Catalonia\u2019s\u00a0BioRegion\u2014centered in Barcelona\u2014represents Spain\u2019s most dynamic ecosystem for\u00a0biotech innovation, with 70% of Spanish biotech companies and several prominent academic and research institutions. The region excels in translational research, clinical trials, and partnership-building across startups, universities, and pharma giants, consolidating its status as the country\u2019s powerhouse in biomedical research and drug development.<\/p>\n<p>These structural advantages confirm the pharmaceutical industry\u2019s strategic significance for both\u00a0Spain and the wider EU, with distinctive leadership in health, employment, technological innovation, and international competitiveness.<\/p>\n<h2><strong>Innovation, R&amp;D, and Clinical Trials<\/strong><\/h2>\n<h3><strong>Spain\u2019s strategy for pharmaceutical innovation<\/strong><\/h3>\n<p>H3 Focus on Research and Development Investments<\/p>\n<p>Spain\u2019s pharmaceutical industry has set a clear strategy of prioritizing\u00a0high investment in research, development, and innovation, with private sector <a href=\"https:\/\/www.efpia.eu\/media\/0ipkatpg\/efpia-ct-report-embargoed-221024-final.pdf\">clinical research<\/a> exceeding\u00a0\u20ac834 million in 2023, up from \u20ac479 million in 2012\u2014a nearly doubling in just ten years. This positioning is reinforced by regular public-private partnerships and a coordinated regulatory framework that accelerates scientific progress. (<\/p>\n<h3><strong>Spain&#8217;s Pharmaceutical Industry Strategy<\/strong><\/h3>\n<p>The national strategy is focused on leveraging Spain\u2019s robust healthcare infrastructure, efficient regulatory environment, and strong R&amp;D ecosystem to position the country as a continental leader in applied biomedical innovation. With the swift adaptation of the and a proactive encouragement of hospital participation, Spain now combines speed, quality, and ethical standards to attract multinational investment, making it a preferred hub for clinical drug development.<\/p>\n<h3><strong>Role of Clinical Trials and Patient-Centered Innovation<\/strong><\/h3>\n<p>By the close of 2023, Spain had authorized\u00a0over trial activity. Major therapeutic areas include oncology, neurology, and rare diseases\u2014with more than\u00a0207 trials focused on rare diseases\u00a0alone. The country\u2019s network of hospitals and health professionals is celebrated for rapid patient recruitment and excellence in trial conduct, granting Spanish patients early access to groundbreaking therapies.<\/p>\n<h3><strong>Leading players in innovation<\/strong><\/h3>\n<ul>\n<li>Grifols: A global leader in plasma-derived therapies and transfusion medicine, headquartered in Barcelona.<\/li>\n<li>Almirall: Specialized in dermatology with strong R&amp;D in immune-inflammatory conditions.<\/li>\n<li>Rovi: Gained international recognition by manufacturing part of the\u00a0Moderna COVID-19 vaccine\u00a0for global distribution.<\/li>\n<li>Rubi\u00f3: A mid-sized Spanish company known for\u00a0R&amp;D collaborations\u00a0and focus on\u00a0innovative neurological and cardiovascular drugs, also engaging in global partnerships to expand therapeutic reach.<\/li>\n<\/ul>\n<p>The focus is not limited to large pharma; Spain has a strong\u00a0biotech start-up ecosystem, particularly in Catalonia and Madrid, fueled by university spin-offs and innovation hubs.<\/p>\n<p>This comprehensive focus on\u00a0innovation, clinical trials, and targeted research investment between 2023 and 2024\u00a0confirms Spain\u2019s standing as the European champion for clinical trial activity, patient-centered biomedical progress, and active international partnerships.<\/p>\n<h2><strong>Regulatory and Institutional Landscape<\/strong><\/h2>\n<h3><strong>Key regulatory bodies<\/strong><\/h3>\n<p>Spain\u2019s pharmaceutical sector operates within a well-structured regulatory and institutional framework that ensures medicines are safe, effective, accessible, and aligned with both national and European Union (EU) standards. The system involves coordination between national agencies, the central government, European institutions, and industry associations.<\/p>\n<h3>The AEMPS is Spain\u2019s national medicines and medical devices agency, operating under the Ministry of Health. Its mandate extends across several responsibilities:<\/h3>\n<ul>\n<li>Evaluation and Authorization: AEMPS assesses new medicines and health products prior to market entry, granting licenses for commercialization.<\/li>\n<li>Monitoring and Oversight: It supervises the safety and quality of medicines throughout their lifecycle, including post-marketing pharmacovigilance.<\/li>\n<li>Clinical Trials Authorization: AEMPS regulates clinical trials in Spain, ensuring they meet ethical and scientific standards.<\/li>\n<li>Inspections and Quality Control: The agency oversees manufacturing sites, distribution channels, and compliance with Good Manufacturing Practices (GMP).<\/li>\n<\/ul>\n<h3>The Ministry of Health defines the broader healthcare and pharmaceutical policy framework, including:<\/h3>\n<ul>\n<li>Pricing and Reimbursement Policies: It establishes mechanisms for negotiating medicine prices, reimbursement conditions, and inclusion in the national health system (SNS).<\/li>\n<li>Strategic Health Policies: Coordinates national plans for healthcare delivery, ensuring equitable access to essential medicines across regions.<\/li>\n<li>Oversight of Public Health Spending: Plays a central role in balancing healthcare sustainability while promoting innovation in pharmaceuticals.<\/li>\n<\/ul>\n<h3><strong>Collaboration with the European Medicines Agency <\/strong>EU Member State, Spain actively contributes to the European regulatory ecosystem:<\/h3>\n<ul>\n<li>Scientific Contribution: Spanish experts, often from AEMPS, serve as rapporteurs and co-rapporteurs in EMA assessments.<\/li>\n<li>Harmonized Approval Procedures: Spain participates in centralized procedures, ensuring medicines approved by the EMA are directly valid in Spain.<\/li>\n<li>Pharmacovigilance Cooperation: Integration with the EU-wide monitoring system allows rapid response to safety issues.<\/li>\n<\/ul>\n<h3><strong>Regulatory and Ethical Compliance Procedures: <\/strong><\/h3>\n<ul>\n<li>EU and National Regulations: Compliance with EU directives and national laws covering safety, efficacy, manufacturing standards, and distribution.<\/li>\n<li>Pharmacovigilance Reporting: Obligations for ongoing safety monitoring and adverse-effect reporting.<\/li>\n<li>Ethical Standards in Clinical Trials: Clinical research is subject to approval by both AEMPS and independent ethics committees, ensuring protection of patient rights and adherence to Good Clinical Practice (GCP).<\/li>\n<li>Transparency Requirements: Regulations promote transparency in interactions between pharmaceutical companies, healthcare professionals, and administrations.<\/li>\n<\/ul>\n<h3><strong>What is the Spanish Association of Pharmaceutical Industry?<\/strong><\/h3>\n<p>The\u00a0Spanish Pharmaceutical Industry Association <a href=\"https:\/\/www.semrush.com\/swa\/checker\/www.farmaindustria.com\">(Farmaindustria)<\/a>\u00a0represents the innovative pharmaceutical sector and plays a central role in shaping the regulatory and institutional environment:<\/p>\n<ul>\n<li>Industry Advocacy: Serves as the main voice of pharmaceutical companies, facilitating dialogue with regulators, policymakers, and healthcare stakeholders.<\/li>\n<li>Ethical and Compliance Framework: Oversees a Code of Good Practices to ensure transparency in relationships with healthcare professionals.<\/li>\n<li>Innovation and Access: Works with governmental bodies to promote patient access to innovative medicines while contributing to the sustainability of the National Health System.<\/li>\n<li>Sector Coordination: Provides statistical insights, supports internationalization, and fosters collaboration in research and development.<\/li>\n<\/ul>\n<h2><strong>Pharmaceutical Manufacturing and Exports<\/strong><\/h2>\n<p>Spain has established itself as a\u00a0manufacturing powerhouse\u00a0within Europe\u2019s pharmaceutical supply chain, combining advanced production capacity with strong international integration. The country offers both scale and specialization, making it one of the EU\u2019s leading contributors to medicine availability worldwide.<\/p>\n<p>H3 Manufacturing capacity<\/p>\n<p><a href=\"https:\/\/manageart.es\/2022\/11\/16\/manageart-presents-study-footprint-pharma-industry-spain\/\">Spain\u2019s industrial<\/a> base for pharmaceuticals is robust and diversified:<\/p>\n<ul>\n<li>Extensive Infrastructure: There are\u00a0over 80 production plants\u00a0located across the country, many of them strategically situated near key logistics hubs such as Barcelona, Madrid, and Valencia.<\/li>\n<li>International Certification: Numerous facilities are\u00a0FDA-approved\u00a0(for the United States) and\u00a0EMA-approved\u00a0(for the EU), enabling Spanish manufacturers to serve regulated global markets.<\/li>\n<li>Specialized Production: Spain stands out for high-value therapeutic categories:<\/li>\n<\/ul>\n<ol>\n<li>Injectables\u00a0(including biologics and vaccines), a growing segment driven by biotechnology.<\/li>\n<li>Oral medicines, supporting both generic and innovative pipelines.<\/li>\n<li>Plasma-derived therapies\u00a0and specialty medicines, where Spain has built significant expertise and lead export volumes in Europe.<\/li>\n<\/ol>\n<ul>\n<li>Innovation and R&amp;D Integration: Many plants are linked to in-house and academic research centers, making Spain a hub where manufacturing and innovation intersect.<\/li>\n<\/ul>\n<h3>Pharmaceutical exports<\/h3>\n<p>In <strong>2023, <\/strong><a href=\"https:\/\/www.statista.com\/statistics\/1231018\/export-value-of-pharmaceutical-products-in-spain-by-country\/\">Spain exported<\/a><strong> \u20ac26.8 billion worth of pharmaceutical products<\/strong>, a record high that reflected <strong>6% year-on-year growth<\/strong>. The <a href=\"https:\/\/www.statista.com\/statistics\/458845\/european-pharmaceutical-markets-turnover\/\">main export markets<\/a> include <strong>Germany, France, Italy, the UK, and the US<\/strong> (<a href=\"http:\/\/www.farmaindustria.es\">).<\/a> Pharmaceuticals have become one of Spain\u2019s <strong>most dynamic and resilient export sectors<\/strong>, continuing to expand even during global downturns such as COVID-19, which reinforced the country\u2019s status as a <strong>reliable EU medicine supplier.<\/strong><\/p>\n<h2><strong> Sustainability and Corporate Responsibility<\/strong><\/h2>\n<p>The pharmaceutical industry in Spain integrates <strong>sustainability<\/strong> and <strong>corporate social responsibility (CSR)<\/strong> into its long-term strategy, reflecting both regulatory pressure and global demand for greener healthcare solutions.<\/p>\n<p>h3 Environmental and social initiatives<\/p>\n<p>Spanish pharmaceutical companies increasingly align with the <strong>United Nations Sustainable Development Goals (SDGs)<\/strong>, particularly <strong>SDG 3 (Good Health and Well-Being)<\/strong>, <strong>SDG 12 (Responsible Consumption and Production)<\/strong>, and <strong>SDG 13 (Climate Action)<\/strong> <a href=\"https:\/\/sdgs.un.org\/goals?utm_source=chatgpt.com\">(United Nations).<\/a><\/p>\n<p>Key initiatives include:<\/p>\n<ul>\n<li><strong>Reducing carbon footprints<\/strong> through low-emission manufacturing processes and the adoption of green chemistry practices. <a href=\"https:\/\/www.farmaindustria.es\/web\/\">Farmaindustria<\/a> reports that more than <strong>60% of pharma facilities in Spain<\/strong> are already implementing energy efficiency plans..<\/li>\n<li><strong>Waste management and recycling programs<\/strong> that target packaging reduction and improved circular economy models.<\/li>\n<li><strong>Energy efficiency and renewable transition<\/strong>, with companies pledging to source more than <strong>50% of electricity from renewables by 2030<\/strong> <a href=\"https:\/\/climate.ec.europa.eu\/index_en?prefLang=es\">(European Commission \u2013 Climate Strategy)<\/a>.<\/li>\n<li><strong>Programs for equitable access to medicines<\/strong>, with industry-wide initiatives supporting affordable treatments, particularly in Latin America and Africa, where Spain has strong trade ties <a href=\"https:\/\/www.efpia.eu\/\">(EFPIA).<\/a><\/li>\n<\/ul>\n<h3><strong>Rubi\u00f3\u2019s Sustainability Role<\/strong><\/h3>\n<p>Few mid-sized pharma companies show the strategic sustainability depth of <strong>Rubi\u00f3<\/strong>. Through its <strong>#Rubi\u00f3ForTheFuture initiative<\/strong>, the company demonstrates that sustainability ambition is not limited to large global firms.<\/p>\n<h3><strong>Key highlights of Rubi\u00f3\u2019s sustainability strategy include:<\/strong><\/h3>\n<ul>\n<li><strong>Commitment to renewable energy:<\/strong> All manufacturing facilities are transitioning to renewable sources, significantly reducing dependence on fossil fuels.<\/li>\n<li><strong>Employee training programs:<\/strong> Rubi\u00f3 invests in sustainability awareness and responsible resource use, embedding environmental responsibility across every level of the organization.<\/li>\n<li><strong>Governance integration:<\/strong> Sustainability is embedded in corporate governance, serving as a <strong>strategic compass<\/strong> rather than a compliance tool. This approach reflects a company culture where environmental and social responsibility are already deeply ingrained<\/li>\n<li>By adopting this comprehensive approach, Rubi\u00f3 positions itself as a benchmark for <strong>sustainability-driven mid-sized pharmaceutical companies in Spain<\/strong>, strengthening its global reputation and competitiveness.<\/li>\n<\/ul>\n<h3><strong>Why It Matters<\/strong><\/h3>\n<p>Sustainability has become a <strong>competitive differentiator<\/strong> in Spain\u2019s pharmaceutical market. With <a href=\"https:\/\/www.statista.com\/topics\/4426\/charlotte-hornets\/\">exports<\/a> representing more than <strong>\u20ac26 billion in 2023<\/strong>, global buyers increasingly favor suppliers with strong environmental and ethical credentials. By embedding CSR practices, Spanish pharma strengthens its <strong>global reputation, supply chain resilience, and compliance with EU Green Deal targets<\/strong>.<\/p>\n<h2><strong>Future Outlook and Challenges<\/strong><\/h2>\n<p>The <strong>Spain pharmacy market outlook<\/strong> points to <strong>digital transformation<\/strong> and innovation as defining forces for the next decade. From <strong>AI-driven drug discovery<\/strong> to <strong>telepharmacy and e-prescriptions<\/strong>, digital tools are reshaping how patients access treatments and how companies deliver care.<\/p>\n<h3>Digital transformation<\/h3>\n<ul>\n<li><strong>AI in drug discovery:<\/strong> GlobalData estimates AI could reduce early-stage R&amp;D timelines by up to <strong>30%<\/strong>, lowering costs and speeding patient access to new therapies according to<\/li>\n<li><strong>E-prescriptions:<\/strong> Over <strong>95% of prescriptions in Spain<\/strong> are already electronic, enabling integration with digital health records and smoother patient care pathways <a href=\"https:\/\/www.oecd.org\/en\/data\/datasets\/oecd-health-statistics.html\">(<\/a><\/li>\n<li><strong>Telepharmacy:<\/strong> Post-COVID, more than <strong>40% of Spanish pharmacies<\/strong> report offering some form of teleconsultation or remote pharmaceutical care ().<\/li>\n<\/ul>\n<h3><strong>Key trends shaping the future<\/strong><\/h3>\n<ul>\n<li><strong>Biosimilars:<\/strong> Spain is a frontrunner in Europe for biosimilar adoption, with biosimilars now covering <strong>over 70% of available biologic molecules<\/strong> and expected to save the healthcare system <strong>billions in <\/strong><a href=\"https:\/\/www.efpia.eu\/\"><strong>annual costs<\/strong> by 2030<\/a>.<\/li>\n<li><strong>Personalized medicine:<\/strong> <a href=\"https:\/\/health.ec.europa.eu\/index_es\">Advances in genomics and digital diagnostics<\/a> are enabling tailored treatments. Spain\u2019s <strong>genomic medicine strategy<\/strong>, backed by public funding of <strong>\u20ac100 million<\/strong>, is set to accelerate adoption by 2025.<\/li>\n<li><strong>Cell and gene therapies:<\/strong> Spain is positioning itself as a European leader in <strong>advanced therapy medicinal products (ATMPs)<\/strong>. The <strong>Spanish Agency of Medicines (AEMPS)<\/strong> has approved more than <strong>30 clinical trials in ATMPs since 2020<\/strong>, making Spain one of the most active EU hubs for these therapies (<\/li>\n<li><strong>Collaborations:<\/strong> Public-private partnerships are expanding, with initiatives like the <strong>PERTE Salud de Vanguardia program<\/strong>, which allocates <strong>\u20ac1.5 billion<\/strong> to accelerate R&amp;D and improve early patient access to breakthrough therapies <a href=\"https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do\">(<\/a><\/li>\n<\/ul>\n<h3><strong>Challenges ahead<\/strong><\/h3>\n<p>Despite rapid growth, challenges remain. <strong>Rising R&amp;D costs, regulatory complexity, and global supply chain vulnerabilities<\/strong> will test Spain\u2019s ability to maintain its strong position. However, sustained investment in <strong>digital innovation, biosimilars, and advanced therapies<\/strong> positions Spain as a <strong>pharmaceutical leader within the EU by 2030<\/strong>.<\/p>\n<h2><strong>Conclusion<\/strong><\/h2>\n<p>The\u00a0pharmaceutical industry in Spain\u00a0is not simply a supplier of medicines\u2014it is a\u00a0pillar of the Spanish economy, a\u00a0key contributor to European health sovereignty, and a\u00a0global innovation hub.<\/p>\n<p>Its strengths include:<\/p>\n<ul>\n<li>A large and competitive\u00a0domestic market with international reach<\/li>\n<li>Strong\u00a0R&amp;D base\u00a0with world-class clinical trial capabilities<\/li>\n<li>Competitive\u00a0manufacturing and export networks<\/li>\n<li>Commitment to\u00a0sustainability and social responsibility<\/li>\n<\/ul>\n<p>The\u00a0Spain pharmacy market outlook\u00a0remains highly positive, pointing to growth in personalized medicine, biosimilars, and digital healthcare. By fostering collaboration between\u00a0public institutions, private companies, and EU partners, Spain is poised to remain at the forefront of the global pharmaceutical stage\u2014delivering both\u00a0health innovations and economic value.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The\u00a0pharmaceutical industry in Spain\u00a0is one of the most dynamic, strategic, and innovation-driven sectors of the nation\u2019s economy. Accordint to Farmaindustria, Investment in R&amp;D by innovative pharmaceutical companies exceeds \u20ac1.5 billion in 2024. Beyond supplying safe and effective medicines to Spanish patients, the sector plays a pivotal role in Europe\u2019s pharmaceutical ecosystem, offering cutting-edge research, production [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3146,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[14],"tags":[],"class_list":["post-3145","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Impact and Relevance of the Pharmaceutical Industry in Spain<\/title>\n<meta name=\"description\" content=\"Explore the profound economical, social, and sustainability impact of the pharmaceutical industry in Spain.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Impact and Relevance of the Pharmaceutical Industry in Spain\" \/>\n<meta property=\"og:description\" content=\"Explore the profound economical, social, and sustainability impact of the pharmaceutical industry in Spain.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/\" \/>\n<meta property=\"og:site_name\" content=\"Laboratorios Rubi\u00f3\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-01T18:46:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T15:47:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.laboratoriosrubio.com\/wp-content\/uploads\/2023\/10\/Pharmaceutical_Industry_In_Spain-1024x683.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"wplabru2020\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"wplabru2020\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/\"},\"author\":{\"name\":\"wplabru2020\",\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/#\\\/schema\\\/person\\\/6000e7d3d6b5bbe767c2c4d76423842c\"},\"headline\":\"The Spanish Pharmaceutical Industry\",\"datePublished\":\"2023-10-01T18:46:21+00:00\",\"dateModified\":\"2026-01-13T15:47:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/\"},\"wordCount\":2953,\"image\":{\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Pharmaceutical_Industry_In_Spain.jpeg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/\",\"url\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/\",\"name\":\"Impact and Relevance of the Pharmaceutical Industry in Spain\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Pharmaceutical_Industry_In_Spain.jpeg\",\"datePublished\":\"2023-10-01T18:46:21+00:00\",\"dateModified\":\"2026-01-13T15:47:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/#\\\/schema\\\/person\\\/6000e7d3d6b5bbe767c2c4d76423842c\"},\"description\":\"Explore the profound economical, social, and sustainability impact of the pharmaceutical industry in Spain.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Pharmaceutical_Industry_In_Spain.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Pharmaceutical_Industry_In_Spain.jpeg\",\"width\":8064,\"height\":5376,\"caption\":\"Scientist hands nanomaterial nano nanotechnology conducting research fiber microfiber microbiology medicine healthcare pharma production lab laboratory science chemistry genetic genes. High quality close-up photo.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/pharmaceutical-industry-in-spain\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Spanish Pharmaceutical Industry\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/\",\"name\":\"Laboratorios Rubi\u00f3\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/#\\\/schema\\\/person\\\/6000e7d3d6b5bbe767c2c4d76423842c\",\"name\":\"wplabru2020\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b904e836584635855eaa0ee2922bae4fe2aa94ffb558048dcc5dac5f98f0fadc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b904e836584635855eaa0ee2922bae4fe2aa94ffb558048dcc5dac5f98f0fadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b904e836584635855eaa0ee2922bae4fe2aa94ffb558048dcc5dac5f98f0fadc?s=96&d=mm&r=g\",\"caption\":\"wplabru2020\"},\"sameAs\":[\"https:\\\/\\\/www.laboratoriosrubio.com\"],\"url\":\"https:\\\/\\\/www.laboratoriosrubio.com\\\/en\\\/author\\\/wplabru2020\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Impact and Relevance of the Pharmaceutical Industry in Spain","description":"Explore the profound economical, social, and sustainability impact of the pharmaceutical industry in Spain.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/","og_locale":"en_US","og_type":"article","og_title":"Impact and Relevance of the Pharmaceutical Industry in Spain","og_description":"Explore the profound economical, social, and sustainability impact of the pharmaceutical industry in Spain.","og_url":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/","og_site_name":"Laboratorios Rubi\u00f3","article_published_time":"2023-10-01T18:46:21+00:00","article_modified_time":"2026-01-13T15:47:47+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/www.laboratoriosrubio.com\/wp-content\/uploads\/2023\/10\/Pharmaceutical_Industry_In_Spain-1024x683.jpeg","type":"image\/jpeg"}],"author":"wplabru2020","twitter_card":"summary_large_image","twitter_misc":{"Written by":"wplabru2020","Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/#article","isPartOf":{"@id":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/"},"author":{"name":"wplabru2020","@id":"https:\/\/www.laboratoriosrubio.com\/en\/#\/schema\/person\/6000e7d3d6b5bbe767c2c4d76423842c"},"headline":"The Spanish Pharmaceutical Industry","datePublished":"2023-10-01T18:46:21+00:00","dateModified":"2026-01-13T15:47:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/"},"wordCount":2953,"image":{"@id":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/#primaryimage"},"thumbnailUrl":"https:\/\/www.laboratoriosrubio.com\/wp-content\/uploads\/2023\/10\/Pharmaceutical_Industry_In_Spain.jpeg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/","url":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/","name":"Impact and Relevance of the Pharmaceutical Industry in Spain","isPartOf":{"@id":"https:\/\/www.laboratoriosrubio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/#primaryimage"},"image":{"@id":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/#primaryimage"},"thumbnailUrl":"https:\/\/www.laboratoriosrubio.com\/wp-content\/uploads\/2023\/10\/Pharmaceutical_Industry_In_Spain.jpeg","datePublished":"2023-10-01T18:46:21+00:00","dateModified":"2026-01-13T15:47:47+00:00","author":{"@id":"https:\/\/www.laboratoriosrubio.com\/en\/#\/schema\/person\/6000e7d3d6b5bbe767c2c4d76423842c"},"description":"Explore the profound economical, social, and sustainability impact of the pharmaceutical industry in Spain.","breadcrumb":{"@id":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/#primaryimage","url":"https:\/\/www.laboratoriosrubio.com\/wp-content\/uploads\/2023\/10\/Pharmaceutical_Industry_In_Spain.jpeg","contentUrl":"https:\/\/www.laboratoriosrubio.com\/wp-content\/uploads\/2023\/10\/Pharmaceutical_Industry_In_Spain.jpeg","width":8064,"height":5376,"caption":"Scientist hands nanomaterial nano nanotechnology conducting research fiber microfiber microbiology medicine healthcare pharma production lab laboratory science chemistry genetic genes. High quality close-up photo."},{"@type":"BreadcrumbList","@id":"https:\/\/www.laboratoriosrubio.com\/en\/pharmaceutical-industry-in-spain\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.laboratoriosrubio.com\/en\/"},{"@type":"ListItem","position":2,"name":"The Spanish Pharmaceutical Industry"}]},{"@type":"WebSite","@id":"https:\/\/www.laboratoriosrubio.com\/en\/#website","url":"https:\/\/www.laboratoriosrubio.com\/en\/","name":"Laboratorios Rubi\u00f3","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.laboratoriosrubio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.laboratoriosrubio.com\/en\/#\/schema\/person\/6000e7d3d6b5bbe767c2c4d76423842c","name":"wplabru2020","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b904e836584635855eaa0ee2922bae4fe2aa94ffb558048dcc5dac5f98f0fadc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b904e836584635855eaa0ee2922bae4fe2aa94ffb558048dcc5dac5f98f0fadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b904e836584635855eaa0ee2922bae4fe2aa94ffb558048dcc5dac5f98f0fadc?s=96&d=mm&r=g","caption":"wplabru2020"},"sameAs":["https:\/\/www.laboratoriosrubio.com"],"url":"https:\/\/www.laboratoriosrubio.com\/en\/author\/wplabru2020\/"}]}},"_links":{"self":[{"href":"https:\/\/www.laboratoriosrubio.com\/en\/wp-json\/wp\/v2\/posts\/3145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.laboratoriosrubio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.laboratoriosrubio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.laboratoriosrubio.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.laboratoriosrubio.com\/en\/wp-json\/wp\/v2\/comments?post=3145"}],"version-history":[{"count":3,"href":"https:\/\/www.laboratoriosrubio.com\/en\/wp-json\/wp\/v2\/posts\/3145\/revisions"}],"predecessor-version":[{"id":4693,"href":"https:\/\/www.laboratoriosrubio.com\/en\/wp-json\/wp\/v2\/posts\/3145\/revisions\/4693"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.laboratoriosrubio.com\/en\/wp-json\/wp\/v2\/media\/3146"}],"wp:attachment":[{"href":"https:\/\/www.laboratoriosrubio.com\/en\/wp-json\/wp\/v2\/media?parent=3145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.laboratoriosrubio.com\/en\/wp-json\/wp\/v2\/categories?post=3145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.laboratoriosrubio.com\/en\/wp-json\/wp\/v2\/tags?post=3145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}